We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosolized monobactam antibiotic]) in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) airway infection
AbstractBackgroundIndividuals with Burkholderia spp. infection have historically been excluded from ...
AbstractBackgroundOpen-label, parallel-group, international trial comparing aztreonam for inhalation...
BackgroundThe objective of this study was to explore the clinical and microbiological outcomes assoc...
We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosoli...
Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with c...
Chronic airway infection with Pseudomonas aeruginosa (PA) causes morbidity and mortality in patients...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not aztreonam lysin...
AbstractBackgroundPrevious aztreonam for inhalation solution (AZLI) studies included patients with c...
Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysre...
AbstractBackgroundConsensus guidelines recommend early treatment to eradicate newly acquired Pseudom...
Background: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...
BACKGROUND: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...
Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in pa...
Chronic airway infection in cystic fibrosis (CF) is a main cause of the increased morbidity and mort...
Inhaled antibiotic therapy in cystic fi-brosis (CF) may be used for multiple indications in patients...
AbstractBackgroundIndividuals with Burkholderia spp. infection have historically been excluded from ...
AbstractBackgroundOpen-label, parallel-group, international trial comparing aztreonam for inhalation...
BackgroundThe objective of this study was to explore the clinical and microbiological outcomes assoc...
We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosoli...
Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with c...
Chronic airway infection with Pseudomonas aeruginosa (PA) causes morbidity and mortality in patients...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not aztreonam lysin...
AbstractBackgroundPrevious aztreonam for inhalation solution (AZLI) studies included patients with c...
Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysre...
AbstractBackgroundConsensus guidelines recommend early treatment to eradicate newly acquired Pseudom...
Background: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...
BACKGROUND: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...
Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in pa...
Chronic airway infection in cystic fibrosis (CF) is a main cause of the increased morbidity and mort...
Inhaled antibiotic therapy in cystic fi-brosis (CF) may be used for multiple indications in patients...
AbstractBackgroundIndividuals with Burkholderia spp. infection have historically been excluded from ...
AbstractBackgroundOpen-label, parallel-group, international trial comparing aztreonam for inhalation...
BackgroundThe objective of this study was to explore the clinical and microbiological outcomes assoc...
DOI
Add to ORKG